High vs. Standard Dose Flu Vaccine for Bone Marrow Transplant Recipients

Phase 2

Waitlist Available

Research Sponsored by Vanderbilt-Ingram Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Allogeneic HSCT recipients who are 3-23 months post-transplant;

≥ 18 years of age;

Timeline

Screening 3 weeks

Treatment Varies

Follow Up nasal swabs were collected at each study visit or within 48 hours if a subject presented with influenza-like symptoms throughout the duration of the study.

Awards & highlights

No Placebo-Only Group

Summary

This trial looks at the side effects and efficacy of two different influenza vaccines in adults who have had a stem cell transplant.

Who is the study for?

This trial is for adults over 18 who had a stem cell transplant between 3 to 23 months ago. They should be available for the study duration and have stable graft-versus-host disease (GVHD) without major treatment changes recently. Participants need a minimum platelet count of 30,000 and must be reachable by phone or electronic means.

What is being tested?

The study compares high-dose trivalent influenza vaccine with standard-dose quadrivalent inactivated flu vaccine in adult stem cell transplant recipients. It aims to see which dosage offers better protection against seasonal flu given their weakened immune systems.

What are the potential side effects?

Potential side effects include typical reactions to vaccines such as soreness at the injection site, fever, muscle aches, and fatigue. There may also be rare risks associated with higher doses of vaccines that will be monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I had a stem cell transplant from a donor between 3 to 23 months ago.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ nasal swabs were collected at each study visit or within 48 hours if a subject presented with influenza-like symptoms throughout the duration of the study.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~nasal swabs were collected at each study visit or within 48 hours if a subject presented with influenza-like symptoms throughout the duration of the study.

This trial's timeline: 3 weeks for screening, Varies for treatment, and nasal swabs were collected at each study visit or within 48 hours if a subject presented with influenza-like symptoms throughout the duration of the study. for reporting.